San Diego, CA, July 16, 2002 — Structural Bioinformatics, Inc. (SBI) announced today its award from the National Institutes of Health (NIH) of a Small Business Innovation Research (SBIR) Phase II grant for SBI’s continued development of an anthrax lethal factor inhibitor. The $754,259 two-year grant is expected to allow SBI to develop a small-molecule nonpeptide inhibitor of anthrax lethal factor (ALF).

The US Patent and Trademark Office’s notice of allowance of patent approval for SBI’s anthrax lethal factor inhibitors was announced by SBI in March, 2002. Patent issuance is expected in the third quarter of 2002.

“This is one of the most important development programs in SBI’s drug pipeline because of its implications for homeland defense,” said Dr. Edward T. Maggio, Chairman and CEO of SBI. “Given recent FDA guidelines to expedite development and review of agents to combat bioterrorism, we are accelerating our ALF program. It is SBI’s intention to develop and commercialize this product on its own,” he added.

About Structural Bioinformatics, Inc.

Structural Bioinformatics, Inc. (SBI) is a world leader in proteomics-driven drug discovery – the large-scale generation and use of protein structural information to accelerate the drug discovery and optimization processes. SBI’s Genes to Leads® technology offers a practical response to the flood of new drug targets emerging from genomic sequencing efforts for the human genome and the genomes of hundreds of infectious disease agents. SBI’s technology reliably produces drug leads – in 60-120 days – starting with the drug target sequence alone, with an efficiency that is more than 1,000-fold greater than state-of-the-art high-throughput screening. SBI’s proprietary computational proteomics platform produces major benefits in pharmaceutical development, speeding drug discovery, reducing costs and increasing the probability of success.

SBI’s drug discovery pipeline is focused on therapeutics for diabetes, cancer, and inflammatory and infectious diseases. SBI further leverages its technologies to create a growing revenue stream through its StructureBank™ 3-D protein structure database management system, and its structural content products – ProMax™ – a comprehensive drug target database, and Variome™ – individual drug target-specific structural pharmacogenomics database modules.

SBI has partnerships with a number of technology leaders in their respective industry segments, including Johnson & Johnson, Boehringer Ingelheim, Janssen Pharmaceutica, De Novo Pharmaceuticals, DuPont Pharmaceuticals, InCyte Genomics, Inc. and Arqule. SBI’s partners include IBM and Quest Diagnostics – both of whom are part of the company’s premier international investor base.

SBI is headquartered in San Diego CA, with offices in Cambridge MA, Washington DC and Hørsholm, Denmark. More information may be found on SBI’s web site at http://www.strubix.com/.